Ph.D., CEO/Co-Founder, Resistance Bio
Biography
Dr. Goldner is a molecular biologist and entrepreneur focused on defeating cancer due to a personal connection. He harnesses evolution to map the cancer resistome, which enables the discovery and development of smarter cancer therapies and diagnostics.
Talk
Clinical Dx Showcase:
Resistance Bio
resistanceBio has developed the ResCu system, a proprietary cancer culture system that predicts resistance mechanisms to novel and existing therapies often not seen until the clinic. When paired with our proprietary algorithm, ResistanceRank, we can identify and rank the importance of resistance mechanisms to identify patients with the highest likelihood of treatment success to a given therapy.
Capturing Cancers Adaptive Resistance Profiles Via the ResSu System
resistanceBio has developed a novel method and algorithm for picking up resistance mechanisms.
Session Abstract – PMWC 2023 Silicon Valley
Showcase Track S2 - January 25 9.00 A.M.-1.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-4.45 P.M.,Showcase Track S2 - January 27 9.00 A.M.-2.15 P.M.
The PMWC 2023 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
